TB006 for autism in adults
Part of Mental health clinical trials.
This study tests an experimental medication called TB006 for adults with autism. It aims to see if it can help reduce symptoms. Participants must be 18–35, have moderate-to-severe autism, and have a caregiver who can join them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 35 years old.
- You must have a diagnosis of Autism Spectrum Disorder that is moderate or severe (but not extremely ill).
- You must have a caregiver who can come with you to all study visits and fill out questionnaires.
- You must not have active epilepsy, genetic syndromes, or major brain malformations.
- You must be willing to use two forms of birth control if sexually active, or not be sexually active.
- Your treatments and therapies (like diet, supplements, or behavioral therapy) must have been stable for at least two months and stay the same during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral liquid medicine (called NTI164) to see if it helps reduce symptoms of autism in children and teens. It may be an option if current treatments haven't fully helped, but it requires regular study visits and certain health rules.
This study tests if a type of brain stimulation (rTMS) guided by brain scans can improve thinking and behavior in people with autism who also have intellectual disability. It aims to help with social communication and daily function.
This trial tests whether low doses of a protein called interleukin-2 (IL-2) can help reduce the symptoms of autism in children aged 6 to 8. It is designed for children whose mothers had a specific immune system condition or a severe infection during pregnancy.
This trial tests a new cell-based treatment (called VGN-Ex05e) for young people with autism who have severe self-injury or aggression that hasn't improved with standard treatments. The treatment is given as a one-time injection into a specific area of the brain (nucleus accumbens) to help calm these behaviors.
This trial tests an experimental drug called DT402 to see if it can improve social and communication skills in adults with autism. You may join if you are between 18 and 65, have a confirmed autism diagnosis, and have noticeable social challenges.
This trial tests if the steroid prednisone can help adults with moderate-to-severe autism who also have signs of immune system problems, like autoimmune disease or inflammation. It might offer a new treatment option for people whose autism is linked to immune activity.
Hear when a new Autism spectrum disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.